Immunome
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 55
- Market Cap
- $899M
- Website
- http://www.immunome.com
- Introduction
Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.
A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants
Phase 1
Active, not recruiting
- Conditions
- Healthy Volunteer
- Interventions
- Drug: varegacestatDrug: Itraconazole (200 mg)
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Immunome, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT06677996
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
IMM-BCP-01 in Mild to Moderate COVID-19
Phase 1
- Conditions
- SARS-CoV2 InfectionCOVID-19
- Interventions
- Drug: IMM-BCP-01Drug: Placebo
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Immunome, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05429021
- Locations
- 🇺🇸
Ark Clinical Research, Long Beach, California, United States
🇺🇸Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸Icahn School of Medicine at Mt. Sinai, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath